The Untold Story of the Paul Weiss Internal Investigation that Didn’t Catch a Massive Stock Fraud | WHAT REALLY HAPPENED

The Untold Story of the Paul Weiss Internal Investigation that Didn’t Catch a Massive Stock Fraud

The legal press has been having a field day with how the U.S. Department of Justice, funded by U.S. taxpayers to conduct its own serious and unbiased investigations, has been outsourcing its investigations to the criminal target and its outside counsel – specifically, the law firm Paul, Weiss, Rifkind, Wharton & Garrison.

The case making the headlines involves Deutsche Bank. But another Paul Weiss internal investigation that has escaped meaningful scrutiny by mainstream media involves China Medical Technologies. The U.S. Department of Justice now describes this company as a massive securities fraud that dates back to the time that Paul Weiss conducted one of its internal investigations and came up empty-handed – or, at least, that’s what China Medical Technologies told the Securities and Exchange Commission in an official filing document.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA